All In Biotech

Drug Trial Radar · NCT06994936

An Open-label Study in Healthy Adults to Evaluate the Relative Bioequivalence of a Single-dose Administration of Sonelokimab Either by a Prefilled Syringe or an Autoinjector

An Open-label, Randomized, Parallel-group, Single-dose Relative Bioequivalence Study of Sonelokimab Administered Subcutaneously Either by a Prefilled Syringe or an Autoinjector in Healthy Adults

Last checked: Nov 19, 2026Latest source record: Dec 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

120

Actual

Start

Jun 5, 2025

Primary completion

Nov 1, 2025

Study completion Nov 1, 2025

Sponsor

Lead sponsor
MoonLake Immunotherapeutics AGIndustry
Sponsor type
Industry
First posted
May 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a study to confirm the relative bioequivalence of sonelokimab administered subcutaneously via a prefilled syringe (PFS) or an autoinjector (AI) in healthy adult volunteers

Conditions

  • Relative Bioequivalence

Interventions

  • SonelokimabDrug

    sonelokimab 120 mg administered subcutaneously via a PFS

  • SonelokimabDrug

    sonelokimab 120 mg administered subcutaneously via an AI

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Comparison of pharmacokinetics (PK) of an AI versus PFS administered single dose of sonelokimabTime frame: 64 days
  2. Comparison of pharmacokinetics (PK) of an AI versus PFS administered single dose of sonelokimabTime frame: 64 days
  3. Comparison of pharmacokinetics (PK) of an AI versus PFS administered single dose of sonelokimabTime frame: 64 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Clinical Site

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.